Crispr Therapeutics AG (CRSP) Stock: Buy, Hold, or Sell?

Monday, May 11, 2020 10:00 AM | InvestorsObserver Analysts

Crispr Therapeutics AG (CRSP) stock has risen 53.09% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 64 out of a possible 100.

That rank is mainly influenced by a long-term technical score of 80. CRSP's rank also includes a short-term technical score of 69. The fundamental score for CRSP is 44. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 72. This means analysts expect the stock to add 24.59% over the next 12 months.

Overall Score - 64
CRSP has an Overall Score of 64. Find out what this means to you and get the rest of the rankings on CRSP!

What's Happening with CRSP Stock Today

Crispr Therapeutics AG (CRSP) stock is up 7.34% while the S&P 500 is down -0.52% as of 9:57 AM on Monday, May 11. CRSP has risen $3.95 from the previous closing price of $53.84 on volume of 120,848 shares. Over the past year the S&P 500 has gained 3.66% while CRSP has risen 53.09%. CRSP earned $0.75 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 76.6.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Related Companies